Actively Recruiting
Study of Zilovertamab Vedotin with Standard Treatments in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Led by Merck Sharp & Dohme LLC · Updated on 2026-11-03
290
Participants Needed
135
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of zilovertamab vedotin ZV combined with standard treatments for participants aged 18 and older who have relapsed or refractory diffuse large B-cell lymphoma rrDLBCL. This Phase 23, randomized, open-label study aims to evaluate the safety and effectiveness of ZV with treatments like rituximab, gemcitabine, and oxaliplatin R-GemOx, or bendamustine and rituximab BR. The study has two parts Dose Confirmation and Efficacy Expansion, focusing on progression-free survival and other outcomes. Participants will receive intravenous infusions of ZV at doses ranging from 1.5 mgkg to 2.5 mgkg along with R-GemOx or BR depending on their assigned group. Treatments are given on Day 1 of repeated 21-day cycles, continuing for up to six cycles or until disease progression or discontinuation. Some participants will receive standard R-GemOx or BR treatments without ZV. Prophylactic granulocyte colony-stimulating factor G-CSF is also given at each cycle of ZV as per guidelines. During the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations over several months. Researchers will measure overall survival, progression-free survival, objective response rate, and duration of response. Participants will be closely followed for up to approximately 68 months to track safety and effectiveness outcomes throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here